Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Predictive Value of XRCC1 and XRCC3 Gene Polymorphisms for Risk of Ovarian Cancer Death After Chemotherapy

  • Cheng, Chun-Xia (Department of Gynecology, Third Xiangya Hospital of Central South University) ;
  • Xue, Min (Department of Gynecology, Third Xiangya Hospital of Central South University) ;
  • Li, Kai (Department of Oncology, Chinese Medical Sciences University) ;
  • Li, Wu-Sheng (Department of Oncology, Chinese Medical Sciences University)
  • Published : 2012.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate any association between XRCC1 and XRCC3 polymorphisms and outcome of platinum-based chemotherapy in ovarian cancer patients. Methods: With a prospective study design was cases were consecutively collected from January 2005 to January 2007. All 310 included patients were followed-up until the end of January 2010. Genotyping of XRCC1 and XRCC3 polymorphisms was conducted by TaqMan Gene Expression assays. Results: A total of 191 patients died during follow-up. Our study showed a lower survival rate in XRCC1 399 Arg/Arg genotype than Gln/Gln, with a significant increased risk of death (HR=1.69, 95%CI=1.07-2.78). Similarly, those carrying XRCC3 Thr/Thr genotype had a increased risk as compare to the Met/Met genotype, with a HR (95% CI) of 1.90 (1.12-3.41). There was no significant association between XRCC1 Arg194Trp and XRCC1Arg280His gene polymorphisms and ovarian cancer death. Conclusion: Our study demonstrates that polymorphisms in DNA repair genes have roles in the susceptibility and survival of ovarian cancer patients.

Keywords

References

  1. Basso D, Navaglia F, Fogar P, et al (2007). DNA repair pathways and mitochondrial DNA mutations in gastrointestinal carcinogenesis. Clin Chim Acta, 381, 50-5. https://doi.org/10.1016/j.cca.2007.02.020
  2. Brenneman MA, Weiss AE, NickoloV JA, et al (2000). XRCC3 is required for eYcient repair of chromosome breaks by homologous recombination. Mutat Res, 459, 89-97. https://doi.org/10.1016/S0921-8777(00)00002-1
  3. Britten RA, Liu D, Tessier A, et al (2000). ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89, 453-7. https://doi.org/10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO;2-E
  4. Cui X, Brenneman M, Meyne J, et al(1999). The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells. Mutat Res, 434, 75-88. https://doi.org/10.1016/S0921-8777(99)00010-5
  5. Giaccone G (2000). Clinical perspectives on platinum resistance. Drugs, 59, 9-17.
  6. Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 1513-30.
  7. Griffin CS, Simpson PJ, Wilson CR, et al (2000). Mammalian recombination- repair genes XRCC2 and XRCC3 promote correct chromosome segregation. Nat Cell Biol, 2, 757-61. https://doi.org/10.1038/35036399
  8. Harries M, Kaye SB (2001). Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs, 10, 1715-24. https://doi.org/10.1517/13543784.10.9.1715
  9. Hoeijmakers JHJ (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74. https://doi.org/10.1038/35077232
  10. Hogberg T, Glimelius B, Nygren P (2001). A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol, 40, 340-60. https://doi.org/10.1080/02841860151116420
  11. Hong YC, Lee KH, Kim WC, et al(2005). Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer, 116, 428-32. https://doi.org/10.1002/ijc.21019
  12. Jacobsen NR, Nexo BA, Olsen A, et al(2003). No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer. Cancer Epidemiol Biomarkers Prev, 12, 584-5.
  13. Jacobsen NR, Raaschou-Nielsen O, Nexo B, et al (2004). XRCC3 polymorphisms and risk of lung cancer. Cancer Lett, 213, 67-72. https://doi.org/10.1016/j.canlet.2004.04.033
  14. Jakubowska A, Gronwald J, Menkiszak J, et al (2010). BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat, 119, 201-11. https://doi.org/10.1007/s10549-009-0390-5
  15. Krivak TC, Darcy KM, Tian C, et al (2011). Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group Study. Gynecol Oncol, 122, 121-6. https://doi.org/10.1016/j.ygyno.2011.03.027
  16. Kubota Y, Nash R, Klungland A, et al (1996). Reconstitution of DNA base-excision repair with purified human proteins: interaction between DNA polymerase b and the XRCC1 protein. EMBOJ, 15, 6662-70.
  17. Kudo K, Gavin E, Das S, et al (2012). Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene, doi: 10.1038/onc.2011.610.
  18. Kuschel B, Auranen A, McBride S, et al (2002). Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet, 11, 1399-407. https://doi.org/10.1093/hmg/11.12.1399
  19. Lee SA, Lee KM, Park SK, et al (2007). Genetic polymorphism of XRCC3 Thr241Met and breast cancer risk: Case-control study in Korean women and meta-analysis of 12 studies. Breast Cancer Res Treat, 103, 71-6. https://doi.org/10.1007/s10549-006-9348-z
  20. Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
  21. Masson M, Niedergang C, Schreiber V, et al (1998). XRCC1 is specifically associated with poly (ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol, 18, 3563-71.
  22. Matullo G, Guarrera S, Carturan S, et al (2001). DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer, 92, 562-7. https://doi.org/10.1002/ijc.1228
  23. Matullo G, Palli D, Peluso M, et al (2001). XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32) P-DNA adducts in a sample of healthy subjects. Carcinogenesis, 22, 1437-45. https://doi.org/10.1093/carcin/22.9.1437
  24. Ryk C, Kumar R, Sanyal S, et al (2006). Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett, 241, 142-9. https://doi.org/10.1016/j.canlet.2005.10.025
  25. Metzger R, Leichman CG, Danenberg KD, et al (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol, 16, 309-16.
  26. Miller SA, Dykes DD, Polesky HF (1998). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
  27. Mort R, Mo L, McEwan C, et al (2003). Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer, 89, 333-7. https://doi.org/10.1038/sj.bjc.6601061
  28. Moullan N, Cox DG, Angele S, et al (2003). Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev, 12, 1168-74.
  29. Piccart MJ, Lamb H, Vermorken JB (2001). Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol, 12, 1195- 203. https://doi.org/10.1023/A:1012259625746
  30. Ratnasinghe D, Yao SX, Tangrea JA, et al (2001). Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 119-23.
  31. Ren S, Zhou S, Zhang L, et al (2010). High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest, 28, 1078-83. https://doi.org/10.3109/07357901003735659
  32. Rosell R, Fossella F, Milas L (2002). Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer, 38, 43-9.
  33. Savas S, Kim DY, Ahmad MF, et al (2004). Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev, 13, 801-7.
  34. Matullo G, Guarrera S, Sacerdote C, et al (2005). Polymorphisms/ haplotypes in DNA repair genes and smoking: A bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev, 14, 2569-78. https://doi.org/10.1158/1055-9965.EPI-05-0189
  35. Shen MR, Jones IM, Mohrenweiser H (1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58, 604-68.
  36. Shirota Y, Stoehlmacher J, Brabender J, et al (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 19, 4298-304.
  37. Siddiqui-Jain A, Bliesath J, Macalino D, et al (2012). CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther, 11, 994-1005. https://doi.org/10.1158/1535-7163.MCT-11-0613
  38. Stern MC, Siegmund KD, Conti DV, et al (2006). XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev, 15, 2384-90. https://doi.org/10.1158/1055-9965.EPI-06-0381
  39. Tudek B (2007). Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med, 28, 258-75. https://doi.org/10.1016/j.mam.2007.05.003
  40. Tuimala J, Szekely G, Gundy S, et al (2002). Genetic polymorphisms of DNA repair and xenobiotic metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis, 23, 1003-8. https://doi.org/10.1093/carcin/23.6.1003
  41. Vogel U, Nexo BA, Wallin H, et al (2004). No association between base excision repair gene polymorphisms and risk of lung cancer. Biochem Genet, 42, 453-60. https://doi.org/10.1023/B:BIGI.0000043957.03420.7e
  42. Winsey SL, Haldar NA, Marsh HP, et al (2000). A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res, 60, 5612-6.
  43. Yeh CC, Sung FC, Tang R, et al (2005). Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan. BMC Cancer, 5, 12. https://doi.org/10.1186/1471-2407-5-12
  44. Zhang L, Zhang Z, Yan W (2005). Single nucleotide polymorphisms for DNA repair genes in breast cancer patients. Clin Chim Acta, 359, 150-5. https://doi.org/10.1016/j.cccn.2005.03.047

Cited by

  1. Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a case–control study in northwest China vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1191-3
  2. Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3707-5
  3. New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins vol.72, pp.9, 2015, https://doi.org/10.1007/s00018-014-1820-z
  4. Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy vol.34, pp.4, 2017, https://doi.org/10.1007/s12032-017-0923-4
  5. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer vol.132, pp.12, 2012, https://doi.org/10.1002/ijc.27980
  6. DNA repair gene XRCC3 Thr241Met polymorphism and susceptibility to glioma: A case-control study vol.8, pp.2, 2014, https://doi.org/10.3892/ol.2014.2192
  7. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy vol.97, pp.45, 2018, https://doi.org/10.1097/MD.0000000000012996